Rosen Law Firm says it filed Unicycive investor class action over OLC claims
Rosen Law Firm said it filed a securities class action against Unicycive Therapeutics over alleged omissions tied to its manufacturing vendor and oxylanthanum carbonate.
Rosen Law Firm said it has filed a securities class action against Unicycive Therapeutics, Inc. on behalf of investors who purchased the company’s securities during a class period from Dec. 29, 2025, through June 29, 2026.
The notice says the case centers on alleged misstatements and omissions about Unicycive’s third-party manufacturing vendor, FDA-related deficiencies and the timing of regulatory approval for oxylanthanum carbonate, or OLC. The firm said investors who bought Unicycive securities may be entitled to participate in the case through a contingency fee arrangement.
The notice says Unicycive had not inspected or audited its vendor’s facility for current good manufacturing practices compliance. It also says the company lacked a reasonable basis to believe the vendor had resolved deficiencies cited by the U.S. Food and Drug Administration.
According to the notice, investors were not told there was a risk the FDA would ask for more information about the facility’s manufacturing practices. It also says approval of OLC was reasonably likely to be delayed. The notice says those alleged details, once disclosed, caused investor damages.
The filing is a litigation allegation notice from the law firm and does not represent an adjudicated finding. Rosen said a class action has already been filed and that investors who want to serve as lead plaintiff must move the court no later than Nov. 2, 2026.
The notice was published Sept. 8, 2026, and identifies the securities as Unicycive common stock traded on Nasdaq under the ticker UNCY. Rosen also provided a web page, phone number and email address for investors seeking information about the case.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.